Joseph G. Pressey · Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients.
Follow
Article1 min read·Published Nov 2026

Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients.

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Nov 2026 · 1 min read

In brief

In brief

This study evaluates zoledronic acid as a therapeutic agent in four patients with metastatic osteosarcoma, demonstrating encouraging progression-free survival outcomes. The bisphosphonate shows promise through multiple mechanisms including direct anti-tumor effects, immune activation, and anti-angiogenic activity.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Zoledronic acid (ZA) is a third-generation bisphosphonate in widespread clinical use to reduce pain and skeletal events in patients from a variety of malignancies with bone metastases. Pre-clinical studies indicate that ZA inhibits osteosarcoma through direct anti-proliferative effects, immune activation and anti-angiogenic activity. The purpose of this study was to evaluate the antitumor efficacy…

Statements in this article

  1. Zoledronic acid is a third-generation bisphosphonate used to reduce pain and skeletal events in patients with bone metastases from various malignancies.

    Established
  2. Pre-clinical studies indicate that zoledronic acid inhibits osteosarcoma through direct anti-proliferative effects, immune activation and anti-angiogenic activity.

    Research

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.